The AI Times is a weekly newsletter covering the biggest AI, machine learning, big data, and automation news from around the globe. If you want to read A|I before anyone else, make sure to subscribe using the form at the bottom of this page.
BetaKit spoke with Louis Têtu about why he thinks tech will emerge as the winner once the COVID-19 storm clears.
NBA announces new multiyear partnership with Microsoft to redefine and personalize the fan experience
“We are thrilled to serve as the official AI partner of the NBA,” said Satya Nadella, CEO, Microsoft. “Together, we’ll bring fans closer to the game and players they love with new personalized experiences powered by Microsoft Azure.”
Machine learning has quickly gone from niche field to crucial component of innumerable software stacks, but that doesn’t mean it’s easy.
If AI is really going to make a difference to patients we need to know how it works when real humans get their hands on it, in real situations.
Four Canadian startups have announced fresh funding rounds to fuel their growth. Here’s the latest on who raised.
The bulk of the capital will be spent on product R&D and sales growth, according to CEO and co-founder Dror Weiss.
Ottawa police say five of its officers tested controversial facial recognition software Clearview AI, according to the results of polling done by the service.
Ada Support has permanently laid off 36 full-time employees, representing just under one-quarter of the company.
Its tech is also aimed at uncovering suspicious patterns of transactions which might indicate a strategic attack on the model itself or an attempt to copy sensitive data.
The goal is to help economists, governments, and others design tax policies that optimize not only productivity and conservation, but that promote widespread, whole-country social equality.
Montreal-based BrainBox AI, which has developed that allows a building’s HVAC system to operate autonomously, has raised $12 million in funding.
Specialists at the London start-up BenevolentAI helped identify the arthritis drug baricitinib, which is now part of a clinical trial.